Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Authors:
Open Access
- 17 July 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (5) , 1255-1276
Abstract
Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports have been published for RA, but not PsA. To inform the real-world safety profile of tofacitinib in PsA, we evaluated AE reports submitted to the Pfizer safety database (including RA data for context). Methods Endpoints included AEs, serious AEs (SAEs), AEs of special interest (AESIs; serious infections, herpes zoster, cardiovascular events, malignancies, venous thromboembolism), and fatal cases. Exposure was estimated using IQVIA global commercial sales data. Number, frequency, and reporting rates (RRs; number of events/100 patient-years’ [PY] exposure) were summarized by indication and formulation (immediate release [IR] 5 or 10 mg twice daily], modified release [MR] 11 mg once daily, or all tofacitinib). The data-collection period differed by indication (PsA: 14 December 2017 [US approval, IR/MR] to 6 November 2021; RA: 6 November 2012 [US approval, IR] to 6 November 2021; MR approval, 24 February 2016). Results A total of 73,525 case reports were reviewed (PsA = 5394/RA = 68,131), with 20,706/439,370 PY (PsA/RA) of exposure. More AEs were reported for IR versus MR (IR/MR: PsA = 8349/7602; RA = 137,476/82,153). RRs for AEs (IR/MR: PsA = 59.6/113.4; RA = 44.0/64.8) and SAEs (PsA = 8.1/13.6; RA = 8.0/9.5) were higher with MR versus IR. AE RRs (RA) in the first 4 years after IR approval were 95.9 (IR; 49,439 PY) and 147.0 (MR; 2000 PY). Frequency of SAEs, AESIs, and fatal cases was mostly similar across formulations and indications. The most frequently-reported AE Preferred Terms (PsA/RA) included drug ineffective (20.0%/17.8%), pain (9.7%/10.6%), condition aggravated (9.9%/10.5%), headache (8.8%/7.9%) and, for PsA, off-label use (10.5%/3.4%). Conclusions Tofacitinib PMS safety data from submitted AE reports were consistent between PsA and RA, and aligned with its known safety profile. Exposure data (lower MR versus IR; estimation from commercial sales data), reporting bias, reporter identity, and regional differences in formulation use limit interpretation.Keywords
Funding Information
- Pfizer
This publication has 72 references indexed in Scilit:
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune‐mediated diseasesArthritis & Rheumatism, 2012
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid ArthritisNew England Journal of Medicine, 2012
- Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritisModern Rheumatology, 2011
- Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in ItalyDrug Safety, 2008
- Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis & Rheumatism, 2007
- Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting DatabasesDrug Safety, 2007
- Epidemiological Aspects of Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2006
- Trends in Spontaneous Adverse Drug Reaction Reports to the French Pharmacovigilance System (1986???2001)Drug Safety, 2005